Sesión Inmunoterapia - Dr. Ralph Mosges
Upcoming SlideShare
Loading in...5
×
 

Sesión Inmunoterapia - Dr. Ralph Mosges

on

  • 1,128 views

Conferencia dictada en el XVII Congreso Latinoamericano de Alergia, Asma e Inmunología, Cartagena, 2012

Conferencia dictada en el XVII Congreso Latinoamericano de Alergia, Asma e Inmunología, Cartagena, 2012

Statistics

Views

Total Views
1,128
Views on SlideShare
865
Embed Views
263

Actions

Likes
1
Downloads
8
Comments
0

7 Embeds 263

http://congresolatinoamericanocartagena.blogspot.com.ar 208
http://congresolatinoamericanocartagena.blogspot.com 28
http://congresolatinoamericanocartagena.blogspot.mx 17
http://congresolatinoamericanocartagena.blogspot.com.br 4
http://congresolatinoamericanocartagena.blogspot.com.es 4
http://10.17.2.44 1
https://www.google.fr 1
More...

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Sesión Inmunoterapia - Dr. Ralph Mosges Sesión Inmunoterapia - Dr. Ralph Mosges Presentation Transcript

  • Prof. Dr. Paolo Falagiani (1947 – 2011)
  • 1: Liccardi G, Passalacqua G, Salzillo A, Piccolo A, Falagiani P, Russo M, 13: Marogna M, Bruno ME, Massolo A, Falagiani P. Sublingual immunotherapy for 25: Bagnasco M, Altrinetti V, Pesce G, Caputo M, Mistrello G, Falagiani P, 40: Tripodi S, Falagiani P, Perinelli T, DellOmo F, Cristaldi A. Allergy toCanonica GW, DAmato G. Is sensitization to furry animals an independent allergic allergic respiratory disease in elderly patients: a retrospective study. Eur Ann Canonica GW, Passalacqua G. Pharmacokinetics of Der p 2 allergen and derived fishing bait. Allergy. 2002 Jul;57(7):653. PubMed PMID: 12100315.phenotype in nonoccupationally exposed individuals? J Investig Allergol Clin Allergy Clin Immunol. 2008 May;40(1):22-9. PubMed PMID: 18700331. monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol. 2005Immunol. 2011;21(2):137-41. PubMed PMID: 21462804. Nov;138(3):197-202. Epub 2005 Oct 3. PubMed PMID: 16205097. 41: Pocobelli D, Del Bono A, Venuti L, Falagiani P, Venuti A. Nasal immunotherapy 14: DAnneo RW, Arena A, Gammeri E, Bruno ME, Falagiani P, Riva G, Leonardi S, La at constant dosage: a double-blind, placebo-controlled study in grass-allergic2: Petrarca C, Lazzarin F, Pannellini T, Iezzi M, Braga M, Mistrello G, Falagiani Rosa M. Parietaria sublingual allergoid immunotherapy with a co-seasonal 26: Passalacqua G, Altrinetti V, Mariani G, Falagiani P, Mistrello G, Brizzolara rhinoconjunctivitis. J Investig Allergol Clin Immunol. 2001;11(2):79-88. PubMedP, Di Giampaolo L, Di Gioacchino M. Monomeric allergoid intragastric treatment schedule. Allergol Immunopathol (Madr). 2008 Mar-Apr;36(2):79-84. R, Canonica GW, Bagnasco M. Pharmacokinetics of radiolabelled Par j 1 PMID: 11642577.administration induces local and systemic tolerogenic response involving PubMed PMID: 18479659. administered intranasally to allergic and healthy subjects. Clin Exp Allergy.IL-10-producing CD4(+)CD25(+) T regulatory cells in mice. Int J Immunopathol 2005 Jul;35(7):880-3. PubMed PMID: 16008673.Pharmacol. 2010 Oct-Dec;23(4):1021-31. PubMed PMID: 21244752. 42: Lombardi C, Gargioni S, Melchiorre A, Tiri A, Falagiani P, Canonica GW, 15: Burastero SE, Mistrello G, Falagiani P, Paolucci C, Breda D, Roncarolo D, Passalacqua G. Safety of sublingual immunotherapy with monomeric allergoid in Zanotta S, Monasterolo G, Rossi RE. Effect of sublingual immunotherapy with grass 27: Asero R, Mistrello G, Roncarolo D, Amato S, Falagiani P. Why do lipid adults: multicenter post-marketing surveillance study. Allergy. 20013: Marogna M, Massolo A, Colombo F, Isella P, Bruno M, Falagiani P. Children monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 transfer protein-hypersensitive patients tolerate bean (and other legumes)? Int Oct;56(10):989-92. PubMed PMID: 11576079.passive smoking jeopardises the efficacy of standard anti-allergic production. Ann Allergy Asthma Immunol. 2008 Apr;100(4):343-50. PubMed PMID: Arch Allergy Immunol. 2005 Jul;137(3):236-40. Epub 2005 Jun 13. PubMed PMID:pharmacological therapy, while sublingual immunotherapy withstands. Allergol 18450120. 15956792.Immunopathol (Madr). 2011 Mar-Apr;39(2):60-7. Epub 2011 Jan 7. PubMed PMID: 43: Asero R, Mistrello G, Roncarolo D, Casarini M, Falagiani P. Allergy to21216083. nonspecific lipid transfer proteins in Rosaceae: a comparative study of different 16: Falagiani P. Nickel hyposensitization: a literature review. Int J 28: Asero R, Mistrello G, Roncarolo D, Amato S, Falagiani P. Detection of novel in vivo diagnostic methods. Ann Allergy Asthma Immunol. 2001 Jul;87(1):68-71. Immunopathol Pharmacol. 2005 Oct-Dec;18(4 Suppl):3-5. Review. PubMed PMID: latex allergens associated with clinically relevant allergy to plant-derived PubMed PMID: 11476467.4: Marogna M, Colombo F, Cerra C, Bruno M, Massolo A, Canonica GW, Falagiani P, 17761097. foods. J Allergy Clin Immunol. 2005 Jun;115(6):1312-4. PubMed PMID: 15940153.Passalacqua G. The clinical efficacy of a sublingual monomeric allergoid atdifferent maintenance doses: a randomized controlled trial. Int J Immunopathol 44: Passalacqua G, Villa G, Altrinetti V, Falagiani P, Canonica GW, Mariani G,Pharmacol. 2010 Jul-Sep;23(3):937-45. PubMed PMID: 20943066. 17: Mistrello G, Harfi H, Roncarolo D, Kwaasi A, Zanoni D, Falagiani P, Panzani 29: Agostinis F, Tellarini L, Canonica GW, Falagiani P, Passalacqua G. Safety of Bagnasco M. Sublingual swallow or spit? Allergy. 2001 Jun;56(6):578. PubMed PMID: R. Date palm pollen allergoid: characterization of its chemical-physical and sublingual immunotherapy with a monomeric allergoid in very young children. 11421908. immunological properties. Int Arch Allergy Immunol. 2008;145(3):224-30. Epub 2007 Allergy. 2005 Jan;60(1):133. PubMed PMID: 15575951.5: Liccardi G, Dente B, Restani P, Senna G, Falagiani P, Ballabio C, DAmato G. Oct 3. PubMed PMID: 17914274.Respiratory allergy induced by exclusive polysensitization to serum albumins of 45: Arena A, Cislaghi C, Falagiani P. Anaphylactic reaction to the ingestion offurry animals. Eur Ann Allergy Clin Immunol. 2010 Jun;42(3):127-30. PubMed PMID: 30: Marogna M, Falagiani P, Bruno M, Massolo A, Riva G. The allergic march in raw onion. A case report. Allergol Immunopathol (Madr). 2000 Sep-Oct;28(5):287-9.20648777. 18: Andri L, Falagiani P. Safety of celecoxib in patients with cutaneous pollinosis: natural history and therapeutic implications. Int Arch Allergy PubMed PMID: 11270091. reactions due to ASA-NSAIDs intolerance. Allergol Immunopathol (Madr). 2007 Immunol. 2004 Dec;135(4):336-42. Epub 2004 Nov 24. PubMed PMID: 15564776. Jul-Aug;35(4):126-9. PubMed PMID: 17663920.6: DAnneo RW, Bruno ME, Falagiani P. Sublingual allergoid immunotherapy: a new 46: Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E, Falagiani4-day induction phase in patients allergic to house dust mites. Int J 31: Lombardi C, Gani F, Landi M, Falagiani P, Bruno M, Canonica GW, Passalacqua P, Mistrello G, Canonica GW, Mariani G. Pharmacokinetics of an allergen and aImmunopathol Pharmacol. 2010 Apr-Jun;23(2):553-60. PubMed PMID: 20646350. 19: Giordano T, Quarta C, Bruno ME, Falagiani P, Riva G. Safety, tolerability and G. Quantitative assessment of the adherence to sublingual immunotherapy. J monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up Allergy Clin Immunol. 2004 Jun;113(6):1219-20. PubMed PMID: 15214362. Allergy. 2001 Jan;31(1):54-60. PubMed PMID: 11167951. phase. Eur Ann Allergy Clin Immunol. 2006 Nov;38(9):310-2. PubMed PMID: 17191751.7: Leonardi S, Arena A, Bruno ME, Cannaò PM, DAnneo RW, Falagiani P, Gammeri E,Mistrello G, Nicolini A, Ricciardi L, Valenti G, Longo R, La Rosa M. Olea 32: Hilger C, Thill L, Grigioni F, Lehners C, Falagiani P, Ferrara A, Romano C, 47: Angiola Crivellaro M, Senna G, Riva G, Cislaghi C, Falagiani P, Waltersublingual allergoid immunotherapy administered with two different treatment 20: Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL, Palma-Carlos ML, Stevens W, Hentges F. IgE antibodies of fish allergic patients cross-react with Canonica G, Passalacqua G. Pollen mixtures used as health food may be a harmfulregimens. Allergy Asthma Proc. 2010 Mar-Apr;31(2):e25-9. PubMed PMID: 20406589. Bruno ME, Falagiani P, Riva G. Clinical efficacy and safety of preseasonal frog parvalbumin. Allergy. 2004 Jun;59(6):653-60. PubMed PMID: 15147451. source of allergens. J Investig Allergol Clin Immunol. 2000 Sep-Oct;10(5):310-1. sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitic PubMed PMID: 11108445. patients. A double-blind, placebo-controlled study. Allergol Immunopathol (Madr).8: Minelli M, Schiavino D, Musca F, Bruno ME, Falagiani P, Mistrello G, Riva G, 2006 Sep-Oct;34(5):194-8. PubMed PMID: 17064648. 33: Andri L, Falagiani P. Symptomatic relief after grass nasal immunotherapy:Braga M, Turi MC, Di Rienzo V, Petrarca C, Schiavone C, Di Gioacchino M. Oral lasting efficacy after 4-5 years. J Investig Allergol Clin Immunol. 48: Senna GE, Andri G, Dama AR, Falagiani P, Andri L. Local nasal immunotherapy:hyposensitization to nickel induces clinical improvement and a decrease in TH1 2003;13(4):228-31. PubMed PMID: 14989110. efficacy and tolerability of two different administration schedules in grassand TH2 cytokines in patients with systemic nickel allergy syndrome. Int J 21: Marogna M, Bruno M, Massolo A, Falagiani P. Long-lasting effects of pollen rhinitis. Allergol Immunopathol (Madr). 2000 Jul-Aug;28(4):238-42. PubMedImmunopathol Pharmacol. 2010 Jan-Mar;23(1):193-201. PubMed PMID: 20378005. sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial PMID: 11022271. hyperreactivity: A long-term (13-year) retrospective study in real life. Int Arch 34: Asero R, Mistrello G, Roncarolo D, Amato S, Falagiani P. Analysis of the heat Allergy Immunol. 2007;142(1):70-8. Epub 2006 Oct 2. PubMed PMID: 17016060. stability of lipid transfer protein from apple. J Allergy Clin Immunol. 20039: Agostinis F, Foglia C, Bruno ME, Falagiani P. Efficacy, safety and Nov;112(5):1009-11. PubMed PMID: 14610497. 49: Corsico R, Falagiani P, Ariano R, Berra D, Biale C, Bonifazi F, Campi P,tolerability of sublingual monomeric allergoid in tablets given without up-dosing Feliziani V, Frenguelli G, Galimberti M, Gallesio MT, Liccardi G, Loreti A,to pediatric patients with allergic rhinitis and/or asthma due to grass pollen. 22: Baruffini A, Pisati G, Russello M, Falagiani P. [Occupational allergic Marcer G, Marcucci F, Meriggi A, Minelli M, Nardelli R, Nardi G, Negrini CA, PapaEur Ann Allergy Clin Immunol. 2009 Dec;41(6):177-80. PubMed PMID: 20128231. IgE-mediated disease from Boletus edulis: case report]. Med Lav. 2005 35: Bagnasco M, Morbelli S, Altrinetti V, Falagiani P, Mariani G, Passalacqua G. G, Piu G, Pozzan M, DAmbrosio FP, Riva G. An epidemiological survey on the Nov-Dec;96(6):507-12. Italian. Erratum in: Med Lav. 2006 Jan-Feb;97(1):87. PubMed Allergen biodistribution in humans. Chem Immunol Allergy. 2003;82:33-43. Review. allergological importance of some emerging pollens in Italy. J Investig Allergol PMID: 16983976. PubMed PMID: 12947990. Clin Immunol. 2000 May-Jun;10(3):155-61. PubMed PMID: 10923590.10: Burastero SE, Mistrello G, Paolucci C, Breda D, Roncarolo D, Zanotta S,Falagiani P. Clinical and immunological correlates of pre-co-seasonal sublingualimmunotherapy with birch monomeric allergoid in patients with allergic 23: Passalacqua G, Pasquali M, Ariano R, Lombardi C, Giardini A, Baiardini I, 36: Ballero M, Ariu A, Falagiani P. Allergy to Ailanthus altissima (tree of 50: Romano C, Ferrara A, Falagiani P. A case of allergy to globe artichoke andrhinoconjunctivitis. Int J Immunopathol Pharmacol. 2009 Apr-Jun;22(2):343-52. Majani G, Falagiani P, Bruno M, Canonica GW. Randomized double-blind controlled heaven) pollen. Allergy. 2003 Jun;58(6):532-3. PubMed PMID: 12757458. other clinical cases of rare food allergy. J Investig Allergol Clin Immunol. 2000PubMed PMID: 19505388. study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due 37: Mistrello G, Roncarolo D, Zanoni D, Zanotta S, Amato S, Falagiani P, Ariano Mar-Apr;10(2):102-4. PubMed PMID: 10879999. to mites. Allergy. 2006 Jul;61(7):849-54. PubMed PMID: 16792583. R. Allergenic relevance of Cupressus arizonica pollen extract and biological characterization of the allergoid. Int Arch Allergy Immunol. 200211: Di Gioacchino M, Perrone A, Petrarca C, Di Claudio F, Mistrello G, Falagiani Dec;129(4):296-304. PubMed PMID: 12483034. 51: Romano C, Ferrara AM, Cislaghi C, Falagiani P. Food allergy to frog. Allergy.P, Dadorante V, Verna N, Braga M, Ballone E, Cavallucci E. Early cytokine 24: Cosmi L, Santarlasci V, Angeli R, Liotta F, Maggi L, Frosali F, Rossi O, 2000 Jun;55(6):584-5. PubMed PMID: 10858996.modulation after the rapid induction phase of sublingual immunotherapy with mite Falagiani P, Riva G, Romagnani S, Annunziato F, Maggi E. Sublingual immunotherapymonomeric allergoids. Int J Immunopathol Pharmacol. 2008 Oct-Dec;21(4):969-76. with Dermatophagoides monomeric allergoid down-regulates allergen-specific 38: Di Rienzo V, Falagiani P, Frati F, Sensi L, Marcucci F. Unusual IgE-mediatedPubMed PMID: 19144282. immunoglobulin E and increases both interferon-gamma- and allergy to fish bait. Allergy. 2002 Sep;57(9):869-70. PubMed PMID: 12169198. 52: Falagiani P. Intranasal immunotherapy. Allergy. 1999;54 Suppl 58:53-5. interleukin-10-production. Clin Exp Allergy. 2006 Mar;36(3):261-72. PubMed PMID: Review. PubMed PMID: 10735653. 16499636.12: Liccardi G, Passalacqua G, Falagiani P, Russo M, DAmato G. The effect of 55: Liccardi G, Russo M, Mistrello G, Falagiani P, DAmato M, DAmato G. 39: Meglio P, Plantamura M, Arabito E, Falagiani P, Torre A, Rossi P. Does SIT tomultiple allergens on histamine release in vivo assessed by skin prick test. Sensitization to pistachio is common in Parietaria allergy. Allergy. 1999 Der p protect from snail sensitization? Allergy. 2002 Sep;57(9):868-9. PubMed 53: Asero R, Mistrello G, Roncarolo D, Casarini M, Falagiani P. TrueAllergy. 2008 Nov;63(11):1559-60. PubMed PMID: 18925893. Jun;54(6):643-5. PubMed PMID: 10435484. PMID: 12169197. monosensitivity to a tropical sole. Allergy. 1999 Nov;54(11):1228-9. PubMed PMID: 10604565.
  • 54: Crimi E, Voltolini S, Minale P, Falagiani P. Value of immunoglobulin E 68: Zardi O, Zardi EM, Falagiani P, Zardi DM, Zardi MC, Barduagni F, Barduagni O. 82: DAmato G, Gentili M, Russo M, Mistrello G, Saggese M, Liccardi G, Falagiani 95: Moscato G, Dellabianca A, Falagiani P, Mistrello G, Rossi G, Rampulla C.density in predicting nasal and bronchial response to inhaled allergens in [Subcutaneous human dirofilariasis]. Pathologica. 1997 Feb;89(1):31-5. Review. P. Detection of Parietaria judaica airborne allergenic activity: comparison Inhaled furosemide prevents both the bronchoconstriction and the increase inrhinitic and asthmatic subjects with multiple sensitizations. Clin Exp Allergy. Italian. PubMed PMID: 9312730. between immunochemical and morphological methods including clinical evaluation. neutrophil chemotactic activity induced by ultrasonic "fog" of distilled water in1999 Dec;29(12):1663-70. PubMed PMID: 10594543. Clin Exp Allergy. 1994 Jun;24(6):566-74. PubMed PMID: 7922776. asthmatics. Am Rev Respir Dis. 1991 Mar;143(3):561-6. PubMed PMID: 2001067. 69: Canonica GW, Passalacqua G, Mariani G, Motta C, Bartolomei M, Mistrello G,55: Liccardi G, Russo M, Mistrello G, Falagiani P, DAmato M, DAmato G. Falagiani P, Bagnasco M. Oral routes for immunotherapy: clinical efficacy and 83: Mistrello G, Roncarolo D, Gentili M, Zanoni D, Falagiani P. Modified par j I 96: Mistrello G, Rapisarda G, Falagiani P. Detection of IgE-binding activity inSensitization to pistachio is common in Parietaria allergy. Allergy. 1999 kinetics of the allergen. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf allergen from P judaica pollen and its rate of absorption in rats. Immunol Lett. serum after intranasal treatment of normal rabbits with P. judaica extract.Jun;54(6):643-5. PubMed PMID: 10435484. A M. 1997;(91):56-64; discussion 64-7. Review. PubMed PMID: 9383892. 1994 Apr;40(1):31-6. Erratum in: Immunol Lett 1994 Jul;41(2-3):291. PubMed PMID: Allergy. 1991 Jan;46(1):52-8. PubMed PMID: 2018209. 7927511.56: Asero R, Mistrello G, Roncarolo D, Antoniotti PL, Falagiani P. A case of 70: Falagiani P, Mistrello G. Pharmacokinetics of allergens after local 84: Costa MA, Colombo P, Izzo V, Kennedy H, Venturella S, Cocchiara R, Mistrello 97: Falagiani P. Thimerosal in standard antigenic extracts. Contact Dermatitis.sesame seed-induced anaphylaxis. Allergy. 1999 May;54(5):526-7. PubMed PMID: administration. Allergy. 1997;52(33 Suppl):17-21. Review. PubMed PMID: 9188942. G, Falagiani P, Geraci D. cDNA cloning, expression and primary structure of Par 1989 Nov;21(5):354. PubMed PMID: 2620521.10380788. jI, a major allergen of Parietaria judaica pollen. FEBS Lett. 1994 Mar 21;341(2-3):182-6. PubMed PMID: 8137937. 71: Liccardi G, Mistrello G, Noschese P, Falagiani P, DAmato M, DAmato G. Oral 98: Cocchiara R, Locorotondo G, Parlato A, Guarnotta G, Ronchi S, Albeggiani G,57: Asero R, Mistrello G, Roncarolo D, Antoniotti P, Cislaghi C, Falagiani P. A allergy syndrome (OAS) in pollinosis patients after eating pistachio nuts: two Amoroso S, Falagiani P, Geraci D. Purification of Parj I, a major allergen fromnew apple extract. Allergy. 1999 Jan;54(1):87-8. PubMed PMID: 10195370. cases with two different patterns of onset. Allergy. 1996 Dec;51(12):919-22. 85: Panzani RC, Mercier P, Delord Y, Riva G, Falagiani P, Reviron D, Auquier P. Parietaria, judaica pollen. Int Arch Allergy Appl Immunol. 1989;90(1):84-90. PubMed PMID: 9020420. Prevalence of patent and latent atopy among a general normal adult population in PubMed PMID: 2478488. the south east of France by RAST investigation and correlation with circulating58: Roncarolo D, Minale P, Mistrello G, Voltolini S, Falagiani P. Food allergy to total IgE levels. Allergol Immunopathol (Madr). 1993 Nov-Dec;21(6):211-9. PubMedBoletus edulis. J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):850-1. PubMed PMID: 72: DAmato G, Russo M, Liccardi G, Saggese M, Gentili M, Mistrello G, DAmato M, PMID: 8160568. 99: Bassoli A, Chioccara F, Di Gregorio G, Rindone B, Tollari S, Falagiani P,9648715. Falagiani P. Comparison between outdoor and indoor airborne allergenic activity. Riva G, Bolzacchini E. Micropreparative-scale enrichment of some allergenic Ann Allergy Asthma Immunol. 1996 Aug;77(2):147-52. PubMed PMID: 8760781. components of Parietaria pollen extract. J Chromatogr. 1988 Jul 27;446:179-85. 86: Caneva E, Di Gennaro P, Farina F, Orlandi M, Rindone B, Falagiani P. PubMed PMID: 3209654.59: Passalacqua G, Bagnasco M, Mariani G, Falagiani P, Canonica GW. Local Synthesis and characterization of a penicillin-poly(L-lysine) which recognizesimmunotherapy: pharmacokinetics and efficacy. Allergy. 1998 May;53(5):477-84. 73: Mistrello G, Brenna O, Roncarolo D, Zanoni D, Gentili M, Falagiani P. human IgE anti-penicillin antibodies. Bioconjug Chem. 1993 Sep-Oct;4(5):309-13.Review. PubMed PMID: 9636806. Monomeric chemically modified allergens: immunologic and physicochemical PubMed PMID: 8274512. 100: Genchi C, Falagiani P, Riva G, Tinelli M, Brunello F, Boero M, Almaviva M. characterization. Allergy. 1996 Jan;51(1):8-15. PubMed PMID: 8721522. IgE and IgG antibodies in Toxocara canis infection. A clinical evaluation. Ann Allergy. 1988 Jul;61(1):43-6. PubMed PMID: 3389570.60: Mistrello G, Gentili M, Roncarolo D, Antoniotti P, Ottoboni F, Falagiani P. 87: Andri L, Senna G, Betteli C, Givanni S, Andri G, Falagiani P. Local nasalDot immunobinding assay for detection of mite antigens in house-dust samples. J 74: Andri L, Senna G, Betteli C, Givanni S, Andri G, Dimitri G, Falagiani P, immunotherapy for Dermatophagoides-induced rhinitis: efficacy of a powderMed Entomol. 1998 Mar;35(2):143-7. PubMed PMID: 9538574. Mezzelani P. Local nasal immunotherapy with extract in powder form is effective extract. J Allergy Clin Immunol. 1993 May;91(5):987-96. PubMed PMID: 8491949. 101: Bassoli A, Chioccara F, Di Gregorio G, Rindone B, Tollari S, Falagiani P, and safe in grass pollen rhinitis: a double-blind study. J Allergy Clin Immunol. Riva G, Bolzacchini E. Analysis of allergenic components of a Parietaria judaica 1996 Jan;97(1 Pt 1):34-41. PubMed PMID: 8568135. pollen extract by chromatographic methods for the evaluation of purification61: Asero R, Mistrello G, Roncarolo D, Antoniotti PL, Falagiani P. A case of 88: Ariano R, Panzani RC, Falagiani P, Chiapella M, Augeri G. Respiratory allergy procedures. J Chromatogr. 1988 Jul 1;444:209-18. PubMed PMID: 3204131.garlic allergy. J Allergy Clin Immunol. 1998 Mar;101(3):427-8. PubMed PMID: to the pollen of Mercurialis annua (Euphorbiaceae). Ann Allergy. 19939525465. 75: Andri L, Senna G, Andri G, Dama A, Givanni S, Betteli C, Dimitri G, Falagiani Mar;70(3):249-54. PubMed PMID: 8452320. P, Mezzelani P. Local nasal immunotherapy for birch allergic rhinitis with 102: Bolzacchini E, Di Gregorio G, Nali M, Rindone B, Tollari S, Falagiani P, extract in powder form. Clin Exp Allergy. 1995 Nov;25(11):1092-9. PubMed PMID: Riva G, Crespi G. Purification and molecular weight studies on the components of62: Pisati G, Baruffini A, Bernabeo F, Falagiani P. Environmental and clinical 8581842. 89: Burastero SE, Lo Pinto G, Goletti D, Cutolo M, Burlando L, Falagiani P. a Parietaria pollen extract. Allergy. 1988 Jan;43(1):53-9. PubMed PMID: 3344935.study of latex allergy in a textile factory. J Allergy Clin Immunol. 1998 Rheumatoid arthritis with monoclonal IgE rheumatoid factor. J Rheumatol. 1993Mar;101(3):327-9. PubMed PMID: 9525447. Mar;20(3):489-94. PubMed PMID: 8386767. 76: Mistrello G, Gentili M, Falagiani P, Roncarolo D, Riva G, Tinelli M. Dot 103: Amoroso S, Cocchiara R, Locorotondo G, Parlato A, Lampiasi N, Albeggiani G, immunobinding assay as a new diagnostic test for human hydatid disease. Immunol Falagiani P, Geraci D. Antigens of Euparipha pisana (snail). I. Identification of63: Coppola V, Veronesi A, Indraccolo S, Calderazzo F, Mion M, Minuzzo S, Lett. 1995 Jul-Aug;47(1-2):79-85. PubMed PMID: 8537105. 90: Panzani RC, Falagiani P, Riva G, Mercier P, Delord. Screening for IgE allergens by means of in vivo and in vitro analysis. Int Arch Allergy ApplEsposito G, Mauro D, Silvestri B, Gallo P, Falagiani P, Amadori A, Chieco-Bianchi mediated allergy among people working in the Marseilles harbour. Allergol Immunol. 1988;85(1):69-75. PubMed PMID: 2448245.L. Lymphoproliferative disease in human peripheral blood mononuclear Immunopathol (Madr). 1993 Jan-Feb;21(1):25-9. PubMed PMID: 8328353.cell-injected SCID mice. IV. Differential activation of human Th1 and Th2 77: Romano C, Sulotto F, Piolatto G, Ciacco C, Capellaro E, Falagiani P,lymphocytes and influence of the atopic status on lymphoma development. J Constable DW, Verga A, Scansetti G. Factors related to the development of 104: Tinelli M, Falagiani P, Riva G, Genchi C. RAST and ELISA in threeImmunol. 1998 Mar 1;160(5):2514-22. PubMed PMID: 9498797. sensitization to green coffee and castor bean allergens among coffee workers. 91: Andri L, Senna GE, Betteli C, Givanni S, Andri G, Falagiani P, Lugo G. Local autochthonous parasitic infections in Italy: toxocariasis, hydatidosis and Clin Exp Allergy. 1995 Jul;25(7):643-50. PubMed PMID: 8521183. nasal immunotherapy in allergic rhinitis to Parietaria. A double-blind controlled fascioliasis. Boll Ist Sieroter Milan. 1987;66(1):38-45. PubMed PMID: 3620121. study. Allergy. 1992 Aug;47(4 Pt 1):318-23. PubMed PMID: 1443452.64: Passalacqua G, Albano M, Pronzato C, Riccio AM, Scordamaglia A, Falagiani P,Canonica GW. Long-term follow-up of nasal immunotherapy to Parietaria: clinical 78: Panzani RC, Falagiani P, Riva G, Delord Y, Mercier P. Screening for atopy in 105: Sgambato F, Pedicini A, De Rienzo D, Falagiani P. [Inhalation allergy to flyand local immunological effects. Clin Exp Allergy. 1997 Aug;27(8):904-8. PubMed a coffee-processing factory. Int Arch Allergy Immunol. 1995 92: Bolzacchini E, Di Gennaro P, Di Gregorio G, Rindone B, Falagiani P, Mistrello larva. A clinical case]. Boll Ist Sieroter Milan. 1987;66(5):411-5. Italian.PMID: 9291287. May-Jun;107(1-3):443-4. PubMed PMID: 7613207. G, Sondergaard I. Purification of Phleum pratense pollen extract by PubMed PMID: 3449104. immunoaffinity chromatography and high-performance ion-exchange chromatography. J Chromatogr. 1991 Jul 12;548(1-2):229-34. PubMed PMID: 1939423. 106: Boner AL, Vallone G, Bennati D, Falagiani P, Gaburro D. Simplified spinhaler65: Bagnasco M, Mariani G, Passalacqua G, Motta C, Bartolomei M, Falagiani P, 79: Ariano R, Panzani RC, Chiapella M, Augeri G, Falagiani P. Local intranasal method for antigen-specific bronchoprovocation in children with bronchial asthma.Mistrello G, Canonica GW. Absorption and distribution kinetics of the major immunotherapy with allergen in powder in atopic patients sensitive to Parietaria I. Ann Allergy. 1986 Nov;57(5):363-6. PubMed PMID: 3777536.Parietaria judaica allergen (Par j 1) administered by noninjectable routes in officinalis pollen. J Investig Allergol Clin Immunol. 1995 May-Jun;5(3):126-32. 93: Del Prete GF, De Carli M, Mastromauro C, Biagiotti R, Macchia D, Falagiani P, 107: Brunello F, Falagiani P, Genchi C. Enzyme immunoassay (ELISA) for thehealthy human beings. J Allergy Clin Immunol. 1997 Jul;100(1):122-9. PubMed PMID: PubMed PMID: 7582157. Ricci M, Romagnani S. Purified protein derivative of Mycobacterium tuberculosis detection of specific IgG antibodies to Toxocara canis ES antigens. Boll Ist9257796. and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T Sieroter Milan. 1986;65(1):54-60. Erratum in: Boll Ist Sieroter Milan 80: Panzani RC, Falagiani P, Riva G, Delord Y, Mercier P. Screening for atopy in cells with stable and opposite (type 1 T helper or type 2 T helper) profile of 1986;65(5):following 445. PubMed PMID: 3718679.66: Asero R, Mistrello G, Roncarolo D, Antoniotti P, Falagiani P. a coffee processing factory. Allergol Immunopathol (Madr). 1995 cytokine production. J Clin Invest. 1991 Jul;88(1):346-50. PubMed PMID: 1829097;Exercise-induced egg anaphylaxis. Allergy. 1997 Jun;52(6):687-9. PubMed PMID: Jan-Feb;23(1):29-34. PubMed PMID: 7631592. PubMed Central PMCID: PMC296040. 08: Genchi C, Tinelli M, Brunello F, Falagiani P. Serodiagnosis of ocular9226076. toxocariasis: a comparison of specific IgE and IgG. Trans R Soc Trop Med Hyg. 1986;80(6):993-4. PubMed PMID: 3603652. 81: Falagiani P, Mistrello G, Rapisarda G, Festa A, Cislaghi C, Zanoni D. 94: Bolzacchini E, Di Gennaro P, Di Gregorio G, Rindone B, Falagiani P, Mistrello67: Asero R, Mistrello G, Falagiani P. Oral allergy syndrome from pork. Allergy. Evaluation of allergenic potency by REAST inhibition. A new tool for the G, Sondergaard I. Allergenic fragments in Parietaria judaica pollen extract. J 109: Falagiani P, Cavallone E, Nali M, Rindone B, Tollari S, Crespi G. Aqueous1997 Jun;52(6):684-6. PubMed PMID: 9226073. standardization of allergenic extracts. J Immunol Methods. 1994 Aug Chromatogr. 1991 Apr 12;542(2):337-44. PubMed PMID: 1715346. size-exclusion analysis of Parietaria pollen extracts. J Chromatogr. 1985 Jun 1;173(2):181-90. PubMed PMID: 8046253. 28;328:425-31. PubMed PMID: 4030974.
  • An impressively productive scientific mind
  • Il dosaggio radio-immunologico delle reagine del secreto nasale.• Boll Soc Ital Biol Sper.• 1977 Feb 15 ; 53(3):188-92.• Crifò S, Falagiani P, Filiaci F, Andriani G.
  • The author of numerous books
  • Concept of themonomeric allergoid
  • The novel view on specificimmunotherapy
  • The first specific sublingual immuntherapywith allergoids available as tablets & drops The Idea: To combine the advantages of allergoids together with the sublingual route into a better effective and more safe Immunotherapy
  • Chemical modification of residual peripheral aminoacid-sequencesReduced IgE binding affinity Maintained conformation for T-cell-binding
  • The first specific sublingual immuntherapy with allergoids available as tablets & drops Sublingual Allergoides Allergens the modified molecule resists to The unmodified molecule is destroyedenzymatic coupling and remains intact. by the attack of enzymes.
  • The first specific sublingual immuntherapy with allergoids available as tablets & drops The novel approach Monomerization (Monoid)Allergen extracts are chemically transformed, theCarbamylation, to replace parts of the proteincomponents, and to maintain the molecular dimensions.
  • Characterization of the sublingual carbamylated allergoid (Monoid)1-Reduction of the Allergenicity2-Maintenance of the Antigenicity3-Maintenance of the Molecular Dimension4-Resistance against Enzymatic Digestion5-Absence of Toxicity
  • Concept Overview Allergenicit Proteine EnzymaticAllergen Type Antigenity y Structure Protection Modified, Reduced complexMonoid Maintained Shown (targeted) („Segments cut“)Native Allergen Maintained Maintained Nativ, complex Not shown Reduced ReducedAllergoid (Not Polymerized Not shown (targeted) targeted)
  • Route of action in the oromucosal and gastrointestinal system APC Lymphozytes oral Lymphatic mucosa systemAllergoid systemic clinical SLIT circulation results gastrointestinal capillaries mucosa
  • Pharmacokinetics & Immunology
  • Clin Exp Allergy 2001, 31; 54-60 Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E, Falagiani P, Mistrello G, Canonica GW, Mariani G.. Clinical Immunology Service, DIMI, Genoa, ItalyObjective To study the pharmacokinetics in allergic volunteers of allergoid sublingual immunotherapy in oromucosal tablets
  • Clin Exp Allergy 2001, 31; 54-60 Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E, Falagiani P, Mistrello G, Canonica GW, Mariani G.. Clinical Immunology Service, DIMI, Genoa, ItalyMethods Radiolabelled monomeric allergoid and native allergen, administered to 8 allergic pts and 1 non atopic, were detected by scintigraphic acquisitions. Plasma radioactivity was measured at different intervals.Results The increased resistance to gastrointestinal enzymatic degradation can explain the high absorption of the monomeric allergoid and its appearance in the bloodstream. The local persistence of the monomeric allergoid and allergen may involve the mucosal immunity in the mechanism of action of antiallergic vaccination.
  • Clin Exp Allergy 2001, 31; 54-60 Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers M. Bagnasco et al. Clinical Immunology Service, DIMI, Genoa, Italy 5- Sublingual allergoidsPlasmatic Radioactivity in form of tablets 3- Native Allergens in liquid solution 1- Native Allergens in form of tablets I I I I 1 2 5 Hrs after application 15 ALLERGO Kinetics
  • Clin Exp Allergy 2001, 31; 54-60 Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers M. Bagnasco et al. Clinical Immunology Service, DIMI, Genoa, ItalyConclusions  Systemic absorption  Mucosal immunity involvement
  • Clin Exp Allergy 2006, 36; 261-272 Sublingual immunotherapy in Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon- and interleukin-10-production. Cosmi L, Santarlasci V, Angeli R, Liotta F, Maggi L, Frosali F, Rossi O, Falagiani P, Riva G, Romagnani S, Annunziato F, Maggi E. Center of Research, Transfer, High Education “DENOthe”, University Firenze, ItalyObjectiveTo show the immunological effects of a sublingual carbamylated allergoid. Methods25 pts: with rhinitis / asthma to Der p1, positive to anamnesis, prick, RAST, SNPT and MCH.Protocol: double blind vs placebo. 1,5 years of treatment.Treated group: 12 Lais Der p1Placebo group: 13
  • Clin Exp Allergy 2006, 36; 261-272 Sublingual immunotherapy in Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon- and interleukin-10-production. L. Cosmi et al. Center of Research, Transfer, High Education “DENOthe”, University Firenze, Italy Resultsthe sublingual allergoid increases theproduction of the cytokines IL-10 & IFN-
  • Clin Exp Allergy 2006, 36; 261-272 Sublingual immunotherapy in Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon- and interleukin-10-production. L. Cosmi et al. Center of Research, Transfer, High Education “DENOthe”, University Firenze, ItalyResults the sublingual allergoid reduces the production of spezific IgE
  • Clin Exp Allergy 2006, 36; 261-272 Sublingual immunotherapy in Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon- and interleukin-10-production. L. Cosmi et al. Center of Research, Transfer, High Education “DENOthe”, University Firenze, ItalyConclusion Clear immunological effects have been shown under treatment with a sublingual carbamylated allergoid.
  • DBPC Trials Results
  • Results from recent (DBPC) TrialsSublingual Allergoidsefficacy (subjective data)• Reduction of symptoms of asthma• Reduction of symptoms of rhinoconjunctivitis• Reduction of symptomatic medication
  • Results from recent (DBPC) TrialsSublingual allergoidsefficacy (objective data)Efficacy was assessed using objective measurements:• increase of the provocative dose specifically in nasal provocation test unspecifically with Metacholine
  • Results from recent (DBPC) TrialsSublingual allergoidsSafetyThe safety of treatment is supported bynumerous published clinical studies.The sublingual allergoid, the Monoid, hasdemonstrated its safety also in patients withOral Allergy Syndrome (OAS).
  • Results from recent (DBPC) TrialsSublingual allergoidsTolerabilityTolerability is supported by data from numerousclinical trials
  • Results from recent (DBPC) TrialsSublingual allergoidsComplianceCompliance, adherence with the treatment is excellent asdemonstrated by:•Pill count in clinical trials.•Repetitive prescription in real life studies.
  • Results from recent (DBPC) Trials
  • Allergy, 2000: 55: 1-6 Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial C.Caffarelli, L.G.Sensi, F.Marcucci, G.Cavagni Paediatric Departments of Parma, Perugia and Sassuolo, ItalyMaterial & methods48 pts: 8 yrs mean age, Rhinoconjunctivitis/Asthma to Grass. DBPC study. Positive anamnesis, SPT and RAST. ECP, symptoms, drug score and Compliance recorded.Protocol: preseasonal scheduling.IT treated: 24 Lais Grass.Drug treated: 20 (4 drop out).
  • Allergy, 2000: 55: 1-6 Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial C.Caffarelli, L.G.Sensi, F.Marcucci, G.Cavagni Paediatric Departments of Parma, Perugia and Sassuolo, ItalyResults Statistically significant differences in Allergoid SLIT treated group: Reduced symptom & medication scores in pollen season Good compliance. No differences in placebo group.
  • Allergy, 2000: 55: 1-6 Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial C.Caffarelli, L.G.Sensi, F.Marcucci, G.Cavagni Paediatric Departments of Parma, Perugia and Sassuolo, Italy 15 - p<0.05score 10 - NS NS 5- p<0.05 NS I I I I I Symptome Symptome Symptome Symptome Rescue medication NASAL OCULAR BRONCHIAL TOTAL Reduction of total symptom score during treatment with sublingual allergoids  vs Placebo  During the grass pollen season.
  • Allergy, 2000: 55: 1-6 Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial C.Caffarelli, L.G.Sensi, F.Marcucci, G.Cavagni Paediatric Departments of Parma, Perugia and Sassuolo, ItalyConclusions The preseasonal course with Lais Grass as Allergoid SLIT: is effective in the reduction of respiratory symptoms of children, in particular asthma, within 3,5 months
  • Allergol et Immunopathol 2006; 34 (5): 194 – 198. Clinical efficacy and safety of preseasonal sublingual immunotherapy with gras pollen carbamylated allergoid in rhinitic patients. A double-blind, placebo-controlled study. Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL, Palma-Carlos ML, Bruno ME, Falagiani P, Riva G. Clinical Allergy Immunology Center. CAIC. Lisbon, PortugalMaterial & Methods 33 pts: with rhinitis / asthma to Phl p5, positive to anamnesis, prick, RAST, SNPT and MCH. Protocol: double blind vs placebo Treated group: 17 Lais 3-Gras Mix Placebo group: 16
  • Allergol et Immunopathol 2006; 34 (5): 194 – 198. Clinical efficacy and safety of preseasonal sublingual immunotherapy with gras pollen carbamylated allergoid in rhinitic patients. A double-blind, placebo-controlled study. Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL, Palma-Carlos ML, Bruno ME, Falagiani P, Riva G. Clinical Allergy Immunology Center. CAIC. Lisbon, PortugalDesign
  • Allergol et Immunopathol 2006; 34 (5): 194 – 198. Clinical efficacy and safety of preseasonal sublingual immunotherapy with gras pollen carbamylated allergoid in rhinitic patients. A double-blind, placebo-controlled study. Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL, Palma-Carlos ML, Bruno ME, Falagiani P, Riva G. Clinical Allergy Immunology Center. CAIC. Lisbon, Portugal Improvement of the nasal provocation testResults Reduction of rhinoconjunctivitis symptoms
  • Allergol et Immunopathol 2006; 34 (5): 194 – 198. Clinical efficacy and safety of preseasonal sublingual immunotherapy with gras pollen carbamylated allergoid in rhinitic patients. A double-blind, placebo-controlled study. A.G. Palma-Carlos, A.S. Santos, M. Branco-Ferreira, A.L. Pregal Clinical Allergy Immunology Center. CAIC. Lisbon, Portugal Reduction of steroid consumptionResults
  • Allergol et Immunopathol 2006; 34 (5): 194 – 198. Clinical efficacy and safety of preseasonal sublingual immunotherapy with gras pollen carbamylated allergoid in rhinitic patients. A double-blind, placebo-controlled study. A.G. Palma-Carlos, A.S. Santos, M. Branco-Ferreira, A.L. Pregal Clinical Allergy Immunology Center. CAIC. Lisbon, PortugalConclusions SLIT in gras allergic patients is effective and reduces single symptoms between 40 - 60 % and co-medication (steroids) vs. placebo up to 80% (at pollen peak)
  • Invest Allergol Clin Immunol, May-June 1998 Vol 8 (3) Efficacy and safety of oral immunotherapy in respiratory allergy to Parietaria judaica pollen. A double blind study R.Ariano*, R.C.Panzani** and C.Augeri* *Allergy Dept., Bordighera, Italy **Lab. De Recherches, Marseille, FranceMaterial & methods 30 pts: with rhinitis / asthma to Par j, positive to anamnesis, prick, RAST, SNPT and MCH. Protocol: double blind vs placebo. Dec.92 to Jul.95. Treated group: 15 Lais Par j (1 drop out). Placebo group: 15
  • Invest Allergol Clin Immunol, May-June 1998 Vol 8 (3) Efficacy and safety of oral immunotherapy in respiratory allergy to Parietaria judaica pollen. A double blind study R.Ariano*, R.C.Panzani** and C.Augeri* *Allergy Dept., Bordighera, Italy **Lab. De Recherches, Marseille, FranceResults Statistically significant differences in the Allergoid SLIT treated group: Reduced symptoms score (in particular during pollen season). Reduced medication score. Increased threshold dose with Allerkin Test. Increased threshold dose with Methacholine Lofarma. No differences in placebo group.
  • Invest Allergol Clin Immunol, May-June 1998 Vol 8 (3) Efficacy and safety of oral immunotherapy in respiratory allergy to Parietaria judaica pollen. A double blind study R.Ariano*, R.C.Panzani** and C.Augeri* *Allergy Dept., Bordighera, Italy **Lab. De Recherches, Marseille, FranceConclusions Hyposensitization with Parietaria pollen as Allergoid SLIT is a safe and efficaceous vaccine which may be used in children and adults.
  • The Lancet Vol.351 Feb 28, 1998 Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in house dust mite - induced rhinoconjunctivitis G. Passalacqua et al. Clinical Immunology Service, DIMI, Genoa, ItalyMaterial & methods 20 pts: per. rhinoconjunctivitis to Der, positive to anamnesis, prick, RAST and SCPT. Inflammatory-cells and ICAM-1 and serum inflam. markers (ECP) recorded. Protocol: double blind vs placebo. Apr.94 to Mar.96. Treated group: 10 Lais Der p&f. Placebo group: 10 (1 drop out).
  • The Lancet Vol.351 Feb 28, 1998 Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in house dust mite - induced rhinoconjunctivitis G. Passalacqua et al. Clinical Immunology Service, DIMI, Genoa, ItalyResults Statistically significant differences in The monomeric Allergoid SLIT group: Reduced symptom & medication scores. Reduced inflammatory infiltration and ICAM-1 expression. Reduced MPI, the Minimal Persistent Inflammation. No differences in placebo group.
  • The Lancet Vol.351 Feb 28, 1998 Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in house dust mite - induced rhinoconjunctivitis G. Passalacqua et al. Clinical Immunology Service, DIMI, Genoa, Italy NEUTROFILE EOSINOFILEICAM 1 0.001 3- p<0.001 3- 10 - 0.001 NS NS 1- NS 1- 5- I I I I I I T0 24 Months T0 24 Months T0 24 Months Reduction of inflammation After 24 months of treatment with sublingual allergoids vs Placebo  Demonstrated by conjunctival provocation test
  • The Lancet Vol.351 Feb 28, 1998 Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in house dust mite - induced rhinoconjunctivitis G. Passalacqua et al. Clinical Immunology Service, DIMI, Genoa, ItalyConclusions Hyposensitization with Dermatophagoides as Allergoid SLIT: l reduces the allergic inflammation l is safe and clinically effective.
  • Giornale Italiano di All e Imm Clin, 2000: 10: S-1 Allergen Specific Oromucosal Immunotherapy: Efficacy and Safety of a Clustered Scheme of Treatment for Parietaria Respiratory Allergy S.D’Agostino, A.D’Agostino, G.Riva. A.Tiri Napoli, Medical Dept Lofarma S.p.A.ItalyMaterial & methods39 pts: Rhinoconjunctivitis / Asthma (50%) to Par. Positive anamnesis, SPT, PFT and SNPT. Serum inflam. markers (ECP) recorded. Symptoms & Drug Score, QoL.Protocol: clustered treatment according to Data Sheet.IT treated: 27 Lais Par.Drug treated: 12 (3 drop out).
  • Giornale Italiano di All e Imm Clin, 2000: 10: S-1 Allergen Specific Oromucosal Immunotherapy: Efficacy and Safety of a Clustered Scheme of Treatment for Parietaria Respiratory Allergy S.D’Agostino, A.D’Agostino, G.Riva. A.Tiri Napoli, Medical Dept Lofarma S.p.A.ItalyResults Statistically significant differences in Allergoid SLIT treated group: Reduced symptom & medication scores. Improved Quality of Life, assessed by questionnaire. Good compliance, over 80% . No differences in placebo group.
  • Giornale Italiano di All e Imm Clin, 2000: 10: S-1 Allergen Specific Oromucosal Immunotherapy: Efficacy and Safety of a Clustered Scheme of Treatment for Parietaria Respiratory Allergy S.D’Agostino, A.D’Agostino, G.Riva. A.Tiri Napoli, Medical Dept Lofarma S.p.A.ItalyConclusions The Clustered Treatment with Parietaria as Allergoid SLIT: l is a suitable treatment when it is too late to start a conventional scheduling l is well tolerated and safe.
  • Giorn it Allergol Immunol Clin 2002; 12:221-226 Safety of Ultra Rush (two hours) Sublingual Swallow Immunotherapy in Allergic Patients R.E. Rossi, G.Monasterolo* Allergy Unit, National Health Service, Savigliano, Italy *Laboratorio Analisi Osp. SS.Trinità, Fossano, ItalyObjective To study the safety of ultra rush SLIT with four commercial products in allergic patients.
  • Giorn it Allergol Immunol Clin 2002; 12:221-226 Safety of Ultra Rush (two hours) Sublingual Swallow Immunotherapy in Allergic Patients R.E. Rossi, G.Monasterolo* Allergy Unit, National Health Service, Savigliano, Italy *Laboratorio Analisi Osp. SS.Trinità, Fossano, ItalyMaterial & Methods Ninety-one allergic patients with rhino-conjunctivitis and/or asthma. Prospective observational, 36 months follow-up study. Maintenance phase from Dec 2001 to Mar 2002. Subdivided in three groups, one was administered the sublingual allergoid, the others, injective I.T. and drugs.
  • Giorn it Allergol Immunol Clin 2002; 12:221-226 Safety of Ultra Rush (two hours) Sublingual Swallow Immunotherapy in Allergic Patients R.E. Rossi, G.Monasterolo* Allergy Unit, National Health Service, Savigliano, Italy *Laboratorio Analisi Osp. SS.Trinità, Fossano, ItalyResults One adverse event, after 300 IR/ml, disappeared when adjusted at 30 IR. No adverse events were noted after administration of the allergoid SLIT.
  • Int Journ of Immunopathology and Pharmacology, 16, 3;, 277-282 Specific Immunotherapy of allergic disease: A three years prospective observational study A. Arena*, E. Barbatano°, E. Gammeri* et al. *ASL 5, Messina, °Pneumologia, Catania, ItalyObjective To evaluate the efficacy, tolerability and adherence to treatment of allergoid sublingual immunotherapy (I.T.), in comparison with injective I.T. and drugs.
  • Int Journ of Immunopathology and Pharmacology, 16, 3;, 277-282 Specific Immunotherapy of allergic disease: A three years perspective observational study A. Arena*, E. Barbatano°, E. Gammeri* et al. *ASL 5, Messina, °Pneumologia, Catania, ItalyMaterial & Methods One hundred and ten allergic patients with rhino- conjunctivitis and/or asthma. Subdivided in three groups, one was administered the sublingual allergoid, the others injective I.T. and drugs. Prospective, observational, 36 months follow-up study. Allergens: pollens and House Dust Mite.
  • Int Journ of Immunopathology and Pharmacology, 16, 3;, 277-282 Specific Immunotherapy of allergic disease: A three years perspective observational study A. Arena*, E. Barbatano°, E. Gammeri* et al. *ASL 5, Messina, °Pneumologia, Catania, ItalyResults Sublingual allergoid I.T. was considered by patients and doctors to be better than the other two therapies (p<0.0001) as far as efficacy, tolerability and patient’s compliance concern.
  • Int Journ of Immunopathology and Pharmacology, 16, 3;, 277-282 Specific Immunotherapy of allergic disease: A three years perspective observational study A. Arena*, E. Barbatano°, E. Gammeri* et al. *ASL 5, Messina, °Pneumologia, Catania, ItalyConclusions Allergoid Sublingual I.T. was positively appreciated by both patients and physicians for its simplicity of use, good efficacy and the high degree of safety offered.
  • SLIT with monomeric allergoid• Effective in rhinoconjunctivitis and asthma• Impeccable safety also in risk populations• Perfectly tolerable in adults and children• Outstanding compliance and adherence• Internationally accepted by – The Paul Ehrlich Institute
  • Paolo Falagiani 1947 - 2011 Thank you for the attention